

PRESS RELEASE



Local Stock and Station Agents Join the Fight Against Cancer

David Nolan is a director of the rma network (rural marketing agents) and Webster Nolan Real Estate is a proud member.

The rma network comprises 140 privately owned stock and station agents' offices with approximately 850 staff located throughout Australia.

The rma network and The Pancare Foundation have joined forces in the fight against cancer and in particular, helping cancer patients in regional Australia.

More than 130 Australians on average die each week from pancreatic, liver, biliary, oesophageal and stomach cancers and the current 5 year survival rate for pancreatic cancer is just 6.1%. The Pancare Foundation is a not for profit organisation working to increase survival rates from pancreatic, liver, biliary, oesophageal and stomach cancers and providing support to people affected by these cancers.

When a patient is diagnosed with cancer it impacts on the whole family and the community in which they live. The Pancare Foundation not only focuses on expediting scientific progress but also the delivery of programs that are designed to address individual and changing patient needs, from the point of diagnosis through to recovery and bereavement.

Over the past three years, The Pancare Foundation has received approximately \$230,000 from the rma network which has been used to expand the Patient Support Meetings, Community Forums Program and the Regional Travel Assistance Program. A proportion of the funds donated were also used to launch the new Pancare Foundation website, acting as a one-stop resource hub for patients and their families.

As a result of this charitable partnership, the rma network are excited to announce the first recipient of the rma network & Pancare Foundation Research Scholarship.



Dr David Lau is the 2015 Research Scholarship recipient. Dr Lau is a qualified medical oncologist enrolled in a PhD at the Olivia Newton-John Cancer Research Institute and La Trobe University. His current work is centred around sequencing the genome of a panel of biliary tract cancer cell lines to discover new therapeutic targets. In addition, he is examining the new multikinase inhibitor, regorafenib in gastric cancers. He hopes to make steady progress and is thankful to the rma network and Pancare for the Scholarship to progress his very important studies.